Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 23;16(9):e0257743. doi: 10.1371/journal.pone.0257743

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Saeed et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 1 — A. Seroprevalence by month over the first COVID-19 wave in Canada by individual assays. Each line represents seroprevalence rates (summarized in table below) monthly between April and September 2020 (during the first COVID-19 Wave) based thresholds for each assay. Abbott Architect SARS-Cov-2 IgG assay (Abbott-NP) and three in-house IgG ELISA assays recognizing distinct recombinant viral antigens: full length spike glycoprotein (Spike), spike glycoprotein receptor binding domain (RBD), and nucleocapsid (NP). B. Seroprevalence by month over the first COVID-19 wave in Canada by various composite reference standards (results from four anti-SARS-CoV-2 immunoassays). Each line represents seroprevalence rates based on predefined definitions. CRS based on a combination of reactive samples using Abbott-NP, Spike, RBD and NP. Positivity based on “any two or more” was determined by a reactive sample from two or more assays. Since we are not comparing CRS, we did not include 95% CI for each data point (all overlapping).